Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).

Amgen takes over multi-specific antibodies through up to $2.5 billion takeout of Teneobio

SOTIO

30/9/2021 | 3 minuty čtení

Vytisknout
Kopírovat odkaz

As multispecific therapies continue to gain traction, Amgen is building out its tool kit through its acquisition of TeneoBio for $900 million up front and $1.6 billion in milestones. Amgen is playing catch-up in hot immuno-oncology areas such as checkpoint inhibitors and CAR-Ts, but it has a first-mover advantage when it comes to bispecifics.

The company was the first to take a bispecific T cell engager (BiTE) over the finish line with FDA’s approval of Blincyto blinatumomab in 2014. antibody-drug conjugates and fusion proteins. The TeneoBio takeout gives Amgen a “heavy-chain only” platform dubbed UniAb, a T cell engager platform and a CD3 engager technology that complements Amgen’s existing suite of multispecific tools. Amgen will also gain TNB-585, a BiTE against PSMA and CD3 in Phase 1 development for metastatic castration-resistant prostate cancer, and several preclinical programs.

TeneoBio plans to spin out three of its pipeline programs into separate entities ahead of the acquisition. CD19 x CD3 bispecific TNB-486, which is in Phase 1 testing for B cell cancers, will become an asset owned by TeneoTwo. Two preclinical programs - an anti-CD38 enzyme inhibitor for metabolic disorders and a bispecific for HBV - will become TeneoFour and TeneoTen respectively. The deal is slated to close by year-end.

Immpact Bio and Kalithera merge to advance to next-generation CAR-Ts

ImmPACT Bio USA and Kalthera merged to advance a combined portfolio of next-generation CAR-T therapies. The deal adds clinical programs to ImmPACT’s pipeline including a Phase 2 bispecific CAR T therapy targeting CD19 and CD20. To support manufacturing for its clinical programs, ImmPACT will move into a new facility in the Los Angeles biotech hub early next year.

PARTNERING

AstraZeneca in-licenses STING inhibitors from F-Star in a $300 million deal


Astrazeneca gets the global rights to research, develop and commercialize protein stimulator of interferon genes, STING inhibitor compounds, from F-star Therapeutics. Astrazeneca is responsible for currently preclinical STING inhibitor compounds from F-star, which retains rights to all its STING agonists in clinical development for treating cancer.

Astrazeneca has not named the indications it intends to target but said it plans to develop therapies across “immune-mediated diseases.” F-star is eligible for up to $12 million in up-front and near-term payments as well as for development and sales milestone payments of more than $300 million, plus single digit percentage royalty payments. F-star’s STING assets came from a reverse merger conducted with Spring Bank Pharmaceuticals that began in July 2020.

BioNTech acquires neoantigen TCR therapy platform from Kite


BioNTech and Kite, a Gilead Company announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen TCR R&D platform and clinical manufacturing facility in Gaithersburg, MD. The acquired Gaithersburg facility will provide production capacity to support clinical trials in the US and will complement BioNTech’s existing cell therapy manufacturing facility in Idar-Oberstein, Germany.

The facility will support the development of BioNTech’s expanding pipeline of novel cell therapies, including cancer product candidates based on its CAR-T Cell amplifying mRNA vaccine (CARVac) and NEOSTIM platforms as well as the newly acquired individualized neoantigen TCR program. Kite will receive a one-time upfront payment from BioNTech to purchase Kite’s individualized solid tumor neoantigen TCR discovery platform as well as the Gaithersburg R&D and clinical manufacturing facility. Financial terms were not disclosed.

Overview of transactions in oncology (values in m$)

Source

Partner

Product

Stage

Rights

Value

UF

MS

Ascentage Pharma Group

Innovent Biologics

License to small molecule BCR-ABL and c-Kit inhibitor olverembatinib and BCL-2 inhibitor lisaftoclax against CML

Filed

CN

195

80

115

Arvinas

Pfizer

License to oral selective estrogen receptor degrader ARV-471 against breast cancer

Ph 2

WW

2,400 1,000 1,400

Teneobio

Amgen

Acquisition of company developing multi-specific antibodies, with lead TNB-486 (CD19xCD3) for B cell cancers

Ph 1

NV

2,500

900

1,600

F-Star Therapeutics

AstraZeneca

License to STING inhibitors for cancer and autoimmune indications

Precl

NW

312

12

300

Kumquat Biosciences

Eli Lilly

License to platform for developing small molecules to treat cancer

Res

WW

2,070

70

2,000

Immorna Biotechnology

Junshi Biosciences

Joint Venture to develop therapies using mRNA technology platform

Res

NV

123

NA

NA

Eureka Therapeutics

Sanofi

License to non-CAR-T rights to a human binding domain against GPRC5D

Res

WW

NA

NA

1,000

NASDAQ Initial Public Offerings (IPOs) in oncology

Company

Ticker

Lead product

Technology

Stage

Amount m$

Price $

Candel Therapeutics

CADL

CAN-2409

Adenovirus-based replication engineered gene construct for PCA

Phase 3

72.0

8

Erasca

ERAS

ERAS-007

Small molecule ERK inhibitor tested against RAS/MAPK altered tumors

Phase 1/2

300.0

16

Caribou Biosciences

CRBU

CD-010

Allogenic anti-CD19 CAR-T evaluated against B cell NHL

Phase 1

304.0

16

Nuvalent

NUVL

NVL-520

Novel brain-penetrant ROS-1 selective inhibitor for ROS1 NSCLC

IND

155.6

17

Tscan Therapeutics

LTCRX

TSC-100

HA-1 specific TCR-T therapy tested on AML, MDS and ALL

IND

100.0

15

Transcode Therapeutics

RNAZ

TTX-MC138

RNA-based candidate focused on metastatic cancer

Preclinical

25.0

4

Sdílet na sociálních sítích

Sdílet na sociálních sítích

Vytisknout

Kopírovat odkaz